| Patient | Jesse Owens |
|---|---|
| Date of birth | 1913-09-12 |
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
| Document date | 1979-07-06 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Runny nose, sore throat and a dry cough for three days, twelve days after the second cycle. [S]
Mr. Owens called the oncology line on day 13 of his second cycle of nivolumab with carboplatin and pemetrexed and was seen the same day, as his warning list asks for any new cough. Three days ago he developed a runny nose and a scratchy throat, and since yesterday a dry cough, worst at night. Several children at a youth club where he spoke last week had colds. His highest temperature at home was 37.8 °C last night. He has no breathlessness: he walked his usual 3 km this morning, a little slower. He has no chest pain, no blood in his sputum, no diarrhea and no rash. He has not smoked since the first cycle and has had no urge to with the cough. He takes varenicline twice daily and had his dexamethasone only around the infusion. He is worried that the cough means the immunotherapy is affecting his lungs. [S]
| Element | Detail |
|---|---|
| Onset | Three days ago, after a youth club visit where several children had colds |
| Severity | Dry cough, worse at night; no breathlessness at rest or on his morning walk |
| Context | Day 13 of cycle 2 of nivolumab with carboplatin and pemetrexed |
| Associated signs and symptoms | Runny nose, sore throat, temperature up to 37.8 °C; no chest pain, hemoptysis, diarrhea or rash |
| Modifying factors | Honey and warm drinks help the throat |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Low-grade temperature to 37.8 °C; tired; no rigors |
| Ears, nose, mouth, and throat | Positive | Runny nose and sore throat; no mouth sores |
| Respiratory | Positive | Dry cough for a day; no breathlessness, wheeze or hemoptysis |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Gastrointestinal | Negative | No diarrhea or abdominal pain |
| Integumentary | Negative | No rash or itching |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 1979-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 1979-06-02 to 1979-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 1979-06-03 to 1979-07-31 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-07-06 | Body height | 178 | cm | S |
| 1979-07-06 | Body weight | 75.6 | kg | S |
| 1979-07-06 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 1979-07-06 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1979-07-06 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1979-07-06 | Heart rate | 84 | /min | S |
| 1979-07-06 | Respiratory rate | 16 | /min | S |
| 1979-07-06 | Body temperature | 37.6 | Cel | S |
| 1979-07-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-07-06 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 13.5-17.5 g/dL | Low | S |
| 1979-07-06 | Leukocytes [#/volume] in Blood by Automated count | 5.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-07-06 | Neutrophils [#/volume] in Blood by Automated count | 3.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-07-06 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
Vital signs recorded on 1979-07-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable, talking in full sentences; temperature 37.6 °C |
| Vital signs | Oxygen saturation 96 percent at rest, as at his earlier visits, and 95 percent after a 6-minute corridor walk; respiratory rate 16 |
| Head, eyes, ears, nose, and throat | Red throat without exudate; clear nasal discharge; no mouth ulcers |
| Neck | No tender or enlarged lymph nodes |
| Respiratory | Clear to auscultation throughout; no crackles or wheeze |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | active | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
| Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | active | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021)
Follow-up: Nurse telephone call in two days. Cycle 3 in nine days. Call the oncology line for any warning sign. Next scheduled visit 1979-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. [S]